Market Overview

UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead

Share:
Related PFE
PreMarket Prep Recap, March 21: We Haven't Seen A 2% Correction Since The Election
Anatomy Of A Decision, Part 1: The C-Suite
Pfizer Is Positioned For Dividend Growth With Limited Downside (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00.

In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income investors over the past two years. Q2'13 earnings look tough in this context and we expect most companies to see some pressure. Novartis, Sanofi, Roche, Abbott, AbbVie and Bayer remain high conviction Buy ideas. We have downgraded Bristol-Myers and Pfizer to Hold in this report as part of our update today.”

Pfizer closed on Thursday at $28.44.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight
Nov 2016ArgusDowngradesBuyHold

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Downgrades Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!